Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Eslicarbazepine Acetate on Gliclazide PK
NCT02777671Phase 1Completed
- Sponsor
- BIAL
- Start
- Oct 2007
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eslicarbazepine acetate in epilepsy (2 arms), sponsored by BIAL. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Maximum Plasma Concentration at 72 hours and 2 more. Started Oct 2007; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02777671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02777671.